Bawan Elayathamby

Associate Director - Global Supply Chain at uniQure

Bawan Elayathamby has a diverse work experience in various industries. Bawan started their career in 2005 at Bank of America as an Operations Representative and later became an Operations Team Manager. In this role, they managed workflow, resolved obstacles, coached and developed associates, and improved performance and productivity. In 2007, they joined Shire as a Manufacturing Technician and was later promoted to Manufacturing Technician II. Bawan contributed to routine and non-routine manufacturing operations, operated and managed production equipment, supported engineering and validation activities, and acted as a subject matter expert for improvement projects. In 2011, Bawan joined Sanofi Genzyme as a Manufacturing Associate and then became a Senior Manufacturing Associate, where they demonstrated leadership and excellence in manufacturing processing, oversaw floor operations, ensured safety and compliance with cGMPs, and efficiently utilized resources. Currently, Bawan works at uniQure as an Associate Director in the Global Supply Chain. Bawan previously held positions as an Associate Director in Manufacturing, a Manager in Manufacturing, a Manufacturing Supervisor, a Manufacturing Specialist, and an Engineer-III R&D. The summary highlights Bawan's progression in their career and showcases their skills and experiences in operations management, manufacturing, leadership, and compliance.

Bawan Elayathamby holds a Master of Science (MS) degree in Regulatory Affairs from Northeastern University. Bawan also has a Bachelor of Science (BS) degree in Biotechnology from the same university. Prior to that, Bawan completed their Associate of Science (AS) degree in Biotechnology at Middlesex Community College.

Location

Saugus, United States

Links

Previous companies


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


uniQure

1 followers

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.


Industries

Employees

201-500

Links


This is an unverified company page